Fibulins and cancer: friend or foe?

被引：122

作者：

Gallagher, WM ^{[1
]}

Currid, CA ^{[1
]}

Whelan, LC ^{[1
]}

机构：

[1] Univ Coll Dublin, Dept Pharmacol, Ctr Mol Med, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland

来源：

TRENDS IN MOLECULAR MEDICINE | 2005年 / 11卷 / 07期

基金：

爱尔兰科学基金会;

关键词：

D O I：

10.1016/j.molmed.2005.06.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The fibulins are a family of secreted glycoproteins, which are characterised by repeated epidermal-growth-factor-like domains and a unique C-terminal structure. Six distinct fibulin genes, encoding at least nine protein products generated by alternative splicing, have been identified. Considerable evidence is available pointing towards a structural role for fibulins within the extracellular matrix. Fibulins have been shown to modulate cell morphology, growth, adhesion and motility. The dysregulation of certain fibulins occurs in a range of human disorders, including cancer. Indeed, both tumour suppressive and oncogenic activities have been proposed for members of the fibulin family. Herein, we discuss the possible roles of fibulins in cancer, in addition to their diagnostic and therapeutic potential.

引用

页码：336 / 340

页数：5

共 40 条

[1] Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells [J].

Albig, AR ;

Schiemann, WP .

DNA AND CELL BIOLOGY, 2004, 23 (06) :367-379

[2] Fibulins: physiological and disease perspectives [J].

Argraves, WS ;

Greene, LM ;

Cooley, MA ;

Gallagher, WM .

EMBO REPORTS, 2003, 4 (12) :1127-1131

[3]

Argraves WS, 2003, FASEB J, V17, pA1172

[4] Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes [J].

Auboeuf, D ;

Dowhan, DH ;

Kang, YK ;

Larkin, K ;

Lee, JW ;

Berget, SM ;

O'Malley, BW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (08) :2270-2274

[5] Transcriptional and Posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells [J].

Bardin, A ;

Moll, F ;

Margueron, R ;

Delfour, C ;

Chu, ML ;

Maudelonde, T ;

Cavailles, V ;

Pujol, P .

ENDOCRINOLOGY, 2005, 146 (02) :760-768

[6]

Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003

[7] The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly [J].

Debeer, P ;

Schoenmakers, EFPM ;

Twal, WO ;

Argraves, WS ;

De Smet, L ;

Fryns, JP ;

Van de Ven, WJM .

JOURNAL OF MEDICAL GENETICS, 2002, 39 (02) :98-104

[8] Interaction of oncogenic papillomavirus E6 proteins with fibulin-1 [J].

Du, MJ ;

Fan, XL ;

Hong, E ;

Chen, JJ .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (04) :962-969

[9] Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum [J].

Forti, S ;

Scanlan, MJ ;

Invernizzi, A ;

Castiglioni, F ;

Pupa, S ;

Agresti, R ;

Fontanelli, R ;

Morelli, D ;

Old, LJ ;

Pupa, SM ;

Ménard, S .

BREAST CANCER RESEARCH AND TREATMENT, 2002, 73 (03) :245-256

[10] MBP1: a novel mutant p53-specific protein partner with oncogenic properties [J].

Gallagher, WM ;

Argentini, M ;

Sierra, V ;

Bracco, L ;

Debussche, L ;

Conseiller, E .

ONCOGENE, 1999, 18 (24) :3608-3616

← 1 2 3 4 →